Persistent residual inflammatory risk at 1 month after contemporary PCI: rationale for routine hsCRP reassessment and dual-target therapy
Despite major advances in lipid-lowering therapy and stent technology, a substantial proportion of patients undergoing contemporary percutaneous coronary intervention (PCI) experience recurrent major adverse cardiovascular events (MACE) driven by persi…